Glembatumumab vedotin represents an new strategy in malignancy therapy. This antibody-drug conjugate carefully recognizes a receptor present on several malignant cells, delivering a potent cytotoxic drug. Preliminary https://www.targetmol.com/compound/glembatumumab_vedotin